{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:07:53Z","timestamp":1746331673372,"version":"3.40.4"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors have been used to treat cancer patients. Non-small cell lung cancer (NSCLC) patients with a high expression level of programmed cell death ligand-1 (PD-L1) could benefit from immune checkpoint inhibitor monotherapy. However, treating NSCLC patients with PD-L1 negative is still a clinical challenge. The utilization of new-type tumor markers as predictive indicators of therapeutic efficacy, with the aim of guiding clinical medication strategies, has emerged as a paramount focus of clinical investigation and interest.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnoses:<\/jats:title>\n            <jats:p>We reported a 72-year-old male with cough diagnosed as poorly differentiated metastatic lung adenocarcinoma (cT3N2M1, stage IV). He tested negative for driver gene mutations, and PD-L1 negative (\uff1c1%), but a high tumor mutational burden (30.9 and 39.1 mutations\/Mb in the lung tissue and blood, respectively), and positive tumor-infiltrating lymphocytes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received pembrolizumab monotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 8 treatment cycles over 5 months, repeat examinations showed significantly reduced lung mass and circulating tumor DNA abundance. The patient reached clinical complete remission and had long-term survival with no significant adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>A comprehensive evaluation of multiple tumor biomarkers should be considered in NSCLC patients. Pembrolizumab monotherapy could benefit NSCLC patients with negative driver genes, PD-L1 negative, a high tumor mutational burden, and positive tumor-infiltrating lymphocytes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040369","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:03:50Z","timestamp":1733778230000},"page":"e40369","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Complete remission after pembrolizumab monotherapy in a non-small cell lung cancer patient with PD-L1 negative, high tumor mutational burden, and positive tumor-infiltrating lymphocytes: A case report"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6174-5036","authenticated-orcid":false,"given":"Suoni","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, Shaanxi Provincial Tumor Hospital, Xi\u2019an, Shaanxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiequn","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shaanxi Provincial Tumor Hospital, Xi\u2019an, Shaanxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shaanxi Provincial Tumor Hospital, Xi\u2019an, Shaanxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shaanxi Provincial Tumor Hospital, Xi\u2019an, Shaanxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-022-29444-9","article-title":"Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.","volume":"13","author":"Mirhadi","year":"2022","journal-title":"Nat Commun"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater.","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy.","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 2.2021.","volume":"19","author":"Ettinger","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur J Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-020-01304-4","article-title":"A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis.","volume":"20","author":"Mei","year":"2021","journal-title":"Mol Cancer"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy.","volume":"26","author":"Liu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer.","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.3390\/cancers13122924","article-title":"Classification of non-small cell lung cancer\u2019s tumor immune micro-environment and strategies to augment its response to immune checkpoint blockade.","volume":"13","author":"Chi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:09:05Z","timestamp":1746320945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":14,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040369","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}